KLRK1 and neoplasm: Having demonstrated that NK cells target osteosarcoma tumour‐initiating cells through NKG2D, Fernández et al. engineered NKG2D‐4‐1BB‐CD3ζ CD45RA− memory CAR T cells to treat this cancer [62].